Form 4: Vericel Corp Director Heidi Hagen Executes Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Director Heidi Hagen exercised stock options and sold shares of Vericel Corp common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On March 3, 2025, Heidi Hagen, a director of Vericel Corp, exercised stock options to acquire 9,000 shares of common stock at a price of $3.74 per share.
- Simultaneously, Hagen sold 9,000 shares of Vericel Corp common stock at a price of $49.53 per share.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 14, 2024.
- Following these transactions, Hagen directly owns 28,650 shares of Vericel Corp common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing insider transactions, which is neutral in sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions and provides transparency to the market regarding the trading activities of company directors.
Stakeholder Impact
- The transactions provide transparency to shareholders regarding insider trading activity.
Key Dates
| Date | Description |
|---|---|
| March 20, 2015 | Date options were originally granted. |
| November 14, 2024 | Date the Rule 10b5-1 trading plan was adopted. |
| March 3, 2025 | Date of the stock option exercise and share sale. |
| March 5, 2025 | Date of the Form 4 filing. |
| March 20, 2025 | Original expiration date of the options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.